Docetaxel (Taxotere®) in the treatment of prostate cancer

References

• Tannock IF, Osoba D, Stockier MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. j Clin. Oncol. 14, 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• •Pivotal Phase III trial that led to the approval of mitoxantrone and prednisone for the palliative treatment of androgen-independent prostate cancer (AIPC).
   Google Scholar
• Kantoff PW, Halabi S, Conaway M et al Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. Clin. Oncol. 17, 2506–2513 (1999).
   Google Scholar
• Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology 60, 94–100 (2002).
   PubMedGoogle Scholar
• •Excellent contemporary review of chemotherapy for prostate cancer.
   Google Scholar
• Petrylak DR Chemotherapy for androgen- independent prostate cancer. Semin. Ural Oncol. 20, 31–35 (2002).
   Google Scholar
• •Excellent contemporary review of chemotherapy for prostate cancer.
   Google Scholar
• Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.J Natl Cancer Inst. 83, 288–291 (1991).
   PubMed Web of Science ®Google Scholar
• Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 32, 2747–2755 (1993).
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. j Clin. Oncol. 17, 1061–1070 (1999).
   PubMed Web of Science ®Google Scholar
• Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after ip. and iv. administration in a rat model. Cancer Chemother. Phatmacol 49, 499–503 (2002).
   Google Scholar
• Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol 28,3–7 (2001).
   PubMed Web of Science ®Google Scholar
• Haldar S, Jena N, Croce CM. Inactivation of Bc1-2 by phosphorylation. Proc. Natl Acad. Sc]. USA 92,4507–4511 (1995).
   Google Scholar
• Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. BE J. Ural 79,196–202 (1997).
   Google Scholar
• Dahllof B, Billstrom A, Cabral F, Hartley- Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53,4573–4581 (1993).
   Google Scholar
• Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 45,3891–3897 (1985).
   PubMed Web of Science ®Google Scholar
• Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 52, 4433–4440 (1992).
   Google Scholar
• Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology48, 164–170 (1996).
   Google Scholar
• Williams JF, Muenchen HJ, Kamradt JM, Korenchuk S, Pienta KJ. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Pmstate 44,275–278 (2000).
   Google Scholar
• Sirotnak FM, Zakowski ME, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (IRESSA), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885–4892 (2000).
   Google Scholar
• O'Donnell RT, DeNardo SJ, Miers LA et al Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50,27–37 (2002).
   PubMed Web of Science ®Google Scholar
• Yu DC, Chen Y, Dilley J et al. Antitumor synergy of CV787, a prostate cancer- specific adenovirus and paclitaxel and docetaxel. Cancer Res. 61,517–525 (2001).
   PubMed Web of Science ®Google Scholar
• Gleave ME, Miayake H, Goldie J, Nelson C, Tokher A. Targeting bc1-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bc1-2 oligodeoxynucleotides. Urology54, 36–46 (1999).
   Google Scholar
• Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin. Oncol 28,49–55 (2001).
   PubMedGoogle Scholar
• Extra JM, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short iv. infusion. Cancer Res. 53, 1037–1042 (1993).
   Google Scholar
• Bissett D, Setanoians A, Cassidy J et al Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 53,523–527 (1993).
   PubMed Web of Science ®Google Scholar
• Pazdur R, Newman RA, Newman BM et al. Phase I trial of taxotere: five-day schedule. .1. Natl Cancer Inst. 84, 1781–1788 (1992).
   Google Scholar
• Burris H, Irvin R, Kuhn J et al Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour iv. infusion. J. Clin. Oncolll, 950–958 (1993).
   Google Scholar
• Tomiak E, Piccart MJ, Kerger J et al. Phase I study of docetaxel administered as a 1-hour iv. infusion on a weekly basis. Clin. Oncol 12,1458–1467 (1994).
   Google Scholar
• Taguchi T, Fume H, Niitani H et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho 21,1997–2005 (1994).
   PubMedGoogle Scholar
• Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Clin. Oncol 16,2164–2168 (1998).
   Google Scholar
• Kraynak MA. Pharmaceutical aspects of docetaxel. Am. J. Health Syst. Pharm. 54, S7—S10 (1997).
   Google Scholar
• Monsarrat B, Royer I, Wright M, Cresteil T Biotransformation of taxoids by human cytochrome P450: structure-activity relationship. Bull Cancer 84,125–133 (1997).
   PubMed Web of Science ®Google Scholar
• Picus J, Schultz M. Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol 26, 14–18 (1999).
   PubMedGoogle Scholar
• Friedland D, Cohen J, Miller R Jr et al. A Phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bc1-2. Semin. Onto]. 26,19-23 (1999).
   Google Scholar
• Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol 12, 1273–1279 (2001).
   PubMed Web of Science ®Google Scholar
• •Phase 11 study of weekly docetaxel with prospectively collected pain and quality of life data.
   Google Scholar
• Berry W Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin. Oncol 28,8–15 (2001).
   Google Scholar
• ••Largest Phase 11 study of weekly docetaxelin AIPC.
   Google Scholar
• Tannock I, Gospodarowicz M, Meakin W et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol 7,590–597 (1989).
   PubMed Web of Science ®Google Scholar
• Sartor 0, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Umlogy52, 252–256 (1998).
   Google Scholar
• Dawson NA, Cooper MR, Figg WD et al Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76, 453–462 (1995).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Curley T, Leibretz C et al Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. j Clin. Oncol 13,2208–2213 (1995).
   PubMed Web of Science ®Google Scholar
• Storlie JA, Buckner JC, Wiseman GA et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76, 96–100 (1995).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Klijn J, Paridaens R et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. j Clin. Oncol 15,3149–3155 (1997).
   PubMed Web of Science ®Google Scholar
• Weitzman AL, Shelton G, Zuech N et al Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J. Ural 163,834–837 (2000).
   PubMed Web of Science ®Google Scholar
• Kreis W, Budman DR, Fetten J et al Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann. °nevi 10, 33–38 (1999).
   Google Scholar
• Petrylak DP, Macarthur RB, O'Connor J et al Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol 17, 958–967 (1999).
   PubMed Web of Science ®Google Scholar
• ••Initial report of the docetaxel plusestramustine regimen that is currently subject to Phase III evaluation in South West Oncology Group trial.
   Google Scholar
• Petrylak DP, Macarthur R, O'Connor J et al Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin. Oncol 26, 28–33 (1999).
   PubMedGoogle Scholar
• Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol 19, 2509–2516 (2001). Robust, multicenter Phase II trial of docetaxel plus estramustine.
   Google Scholar
• Sinibaldi VJ, Carducci MA, Moore-Cooper S et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94,1457–1465(2002).
   PubMed Web of Science ®Google Scholar
• Copur MS, Ledakis P, Lynch J et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin. Oncol 28, 16–21 (2001).
   Google Scholar
• Oudard S, Banu E, Vannetzel JM et al Results of a Phase II randomized trial of docetaxel (D), Estramustine (E) and prednisone (P) — two schedules — versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Ann. Oncol 13\(Suppl. 5), 90 (2002).
   Google Scholar
• Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin. Oncol 28, 56–61 (2001).
   Google Scholar
• Figg WD, Arlen P, Gulley J et al. A randomized Phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. 28, 62–66 (2001). SiTolcher AW. Preliminary Phase I results of G3139 (bc1-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 28, 67–70 (2001).
   Google Scholar
• Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin. Oncol 28, 71–76 (2001).
   Google Scholar
• Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol 21, 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930–942 (1998).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Clark PE, Peereboom DM, Dreicer R et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology57, 281–285 (2001).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Klein EA. Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. Semin. Oncol 28, 45–48 (2001).
   Google Scholar
• Oh WK, George DJ, Kaufman DS et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin. Oncol 28, 40–44 (2001).
   PubMed Web of Science ®Google Scholar
• El-Rayes B, Hussain M, Smith D et al. Neo-adjuvant docetaxel and estramustine in patients with high risk/locally advanced prostate cancer. Proc. Am. Soc. Clin. 194a (2002).
   Google Scholar
• DiBiase S, Dawson N, Hussain A, Jacobs S, Naslund M. A Phase II study evaluating external radiation and transperineal implantation with adjuvant docetaxel and total androgen suppression in patients with poor prognosis non-metastatic prostate cancer. Proc. Am Soc. Clin. Oncol 21 (2002) (Abstract 2487).
   Google Scholar
• Kumar P, Perotti M, Weiss R et al. A novel therapeutic strategy testing the safety and feasibility of concurrent docetaxel and 3-D conformal radiation therapy (RI) in patients with high risk localized adenocarcinoma of the prostate: progress report of an on-going Phase I trial. Proc. Am. Soc. Clin. Oncol 21, 194a (2002).
   Google Scholar
• Hussain A, Dawson N, Amin P et al. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Semin. 28, 22–31 (2001).
   Google Scholar
• Taplin ME, Bubley GJ, Rajeshkumar B et al Docetaxel, estramustine and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. Semin. Oncol 28, 32–39 (2001).
   PubMedGoogle Scholar
• Fumoleau P. Efficacy and safety of docetaxel in clinical trials. Am. J. Health Syst. Pharm. 54, S19—S24 (1997).
   Google Scholar
• Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook (7th Edition). LexiComp, Inc., Hudson, OH, USA, (1999).
   Google Scholar